Comera Life Sciences Holdings, Inc.
CMRAW
NASDAQ Global Market0.02
USD
- -
- -
Comera Life Sciences Holdings, Inc.
CMRAW
(NASDAQ Global Market)
Recent
price
0.02
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Comera Life Sciences Holdings, Inc. is a preclinical biotechnology company focused on developing proprietary drug-delivery technologies to improve patient access, safety, and convenience. The company specializes in transforming intravenous biologic medicines into subcutaneous formulations through its SQore technology platform, which is designed to enable self-administration of biologic therapies. Comera's main products and services include its proprietary SQore excipients and formulation platform used to develop subcutaneous versions of biologic drugs, with applications in inflammatory bowel disease and other therapeutic areas. The company conducts research and development in advanced biologic medicines, particularly targeting musculoskeletal, immunological, and autoimmune disorders. Founded in 2014 and headquartered in Woburn, Massachusetts, Comera operates primarily in the life sciences and biotechnology sectors. Its strategic offerings include licensing the SQore platform to pharmaceutical partners, aiming to improve patient convenience and reduce dependence on intravenous administration in clinical settings. Key recent corporate changes include a bridge financing secured in early 2024, followed by the exercise of a purchase option by investors to take the company private. Comera has also established a partnership with Quality Chemical Laboratories to secure GMP manufacturing and supply of its lead SQore excipients, enhancing control over its proprietary technology supply chain. The company announced strategic research collaborations with top global pharmaceutical companies to develop subcutaneous formulations of biologics using its SQore platform, expanding its pipeline and enhancing product development capabilities. Comera continues to advance preclinical studies demonstrating the safety and efficacy of its caffeine-based SQore excipients and is expanding its intellectual property portfolio with over 20 patents. These developments position Comera as a leading innovator in advancing subcutaneous biologic therapies with potential applications in multiple therapeutic areas globally.